Rein Therapeutics (RNTX) Retained Earnings (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Retained Earnings of -$62000.0 for Q1 2026, up 99.98% year-over-year from -$31002.7 in Q1 2025, and little changed quarter-over-quarter from -$62000.0 in Q4 2025.
Rein Therapeutics (RNTX) Retained Earnings (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Retained Earnings for 11 consecutive years, with -$62000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 99.98% year-over-year to -$62000.0; the TTM figure through Mar 2026 stood at -$62000.0 (up 99.98% YoY), while the FY2025 annual figure was -$62000.0, up 99.98% from the prior year.
- Retained Earnings held at -$62000.0 in Q1 2026 per RNTX's latest filing, from -$62000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at -$44000.0 in Q2 2025 and bottomed at -$356.9 million in Q1 2025.
- Historically, Retained Earnings has averaged -$173.3 million across 5 years, with a median of -$261.9 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings sank 4364600.0% — and 2025, when it surged 99.99%.
- Rein Therapeutics' Retained Earnings stood at -$48000.0 in 2022, then plunged by 31.25% to -$63000.0 in 2023, then tumbled by 557677.78% to -$351.4 million in 2024, then surged by 99.98% to -$62000.0 in 2025, then changed by 0.0% to -$62000.0 in 2026.
- Business Quant data shows RNTX's Retained Earnings at -$62000.0 in Q1 2026, -$62000.0 in Q4 2025, and -$44000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -413.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -413.48 Mn |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -62,000.00 |
| Sep 30, 2025 | -44,000.00 |
| Jun 30, 2025 | -44,000.00 |
| Mar 31, 2025 | -356.90 Mn |
| Dec 31, 2024 | -351.40 Mn |
| Sep 30, 2024 | -310.42 Mn |
| Jun 30, 2024 | -304.57 Mn |
| Mar 31, 2024 | -63,000.00 |
| Dec 31, 2023 | -63,000.00 |
| Sep 30, 2023 | -281.18 Mn |
| Jun 30, 2023 | -279.35 Mn |
| Mar 31, 2023 | -277.56 Mn |
| Dec 31, 2022 | -48,000.00 |
| Sep 30, 2022 | -268.24 Mn |
| Jun 30, 2022 | -261.87 Mn |
| Mar 31, 2022 | -253.88 Mn |
| Dec 31, 2021 | -13,000.00 |
| Sep 30, 2021 | -238.66 Mn |